Brief: Ryvu Therapeutics "Dualis" Project Recommended For 22.2 Mln Zloty Subsidy
07/09/2026 17:01
BRIEF-Ryvu Therapeutics "Dualis" Project Recommended For 22.2 Mln Zloty Subsidy Sept 7 (Reuters) - Ryvu Therapeutics SA RVU.WA:
ITS DUALIS PROJECT RECOMMENDED FOR ABOUT 22.2 MILLION ZLOTY SUBSIDY BY POLISH AGENCY FOR ENTERPRISE DEVELOPMENT
TOTAL NET VALUE OF DUALIS PROJECT IS 30.9 MILLION ZLOTYS
PROJECT AIMS TO DEVELOP AND IMPLEMENT TECHNOLOGY PLATFORM DESIGNED TO ACCELERATE AND ENHANCE EFFICIENCY OF DISCOVERING NEXT-GENERATION BIVALENT PAYLOADS FOR USE IN ANTIBODY-DRUG CONJUGATES (ADCS) IN ONCOLOGY
Source text: ID:nEM7y0l1la
Further company coverage: RVU.WA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Ryvu Therapeutics SA
See all newsBrief: Ryvu Therapeutics Signs Grant Agreement For Panacea-Novo Project With The National Center For Research And Development
Brief: Ryvu Therapeutics Q2 Net Loss 13.1 Million Zlotys
Brief: Ryvu Therapeutics "Dualis" Project Recommended For 22.2 Mln Zloty Subsidy
Brief: Ryvu Therapeutics Launches Early Clinical Development Services Business For Biotech And Pharma In Europe
Brief: Ryvu Therapeutics Says Panacea-Novo Project Recommended For Funding Of 106.7 Mln Zlotys